CytomX Therapeutics (CTMX) EBT Margin (2016 - 2025)
Historic EBT Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 237.65%.
- CytomX Therapeutics' EBT Margin fell 2549900.0% to 237.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.87%, marking a year-over-year increase of 129800.0%. This contributed to the annual value of 23.24% for FY2024, which is 199600.0% up from last year.
- Per CytomX Therapeutics' latest filing, its EBT Margin stood at 237.65% for Q3 2025, which was down 2549900.0% from 0.49% recorded in Q2 2025.
- CytomX Therapeutics' EBT Margin's 5-year high stood at 49.72% during Q4 2024, with a 5-year trough of 353.77% in Q1 2022.
- Its 5-year average for EBT Margin is 117.51%, with a median of 25.81% in 2024.
- Per our database at Business Quant, CytomX Therapeutics' EBT Margin plummeted by -2680400bps in 2021 and then skyrocketed by 3396800bps in 2023.
- CytomX Therapeutics' EBT Margin (Quarter) stood at 312.82% in 2021, then skyrocketed by 86bps to 43.61% in 2022, then surged by 116bps to 7.16% in 2023, then skyrocketed by 594bps to 49.72% in 2024, then plummeted by -578bps to 237.65% in 2025.
- Its last three reported values are 237.65% in Q3 2025, 0.49% for Q2 2025, and 46.32% during Q1 2025.